Co-targeting PARP and SHP2 Overcomes Resistance to Apoptosis and Induces Durable Responses in Breast Cancer.
Resistance to therapeutic interventions contributes to poor long-term cancer patient outcomes. Adaptation to therapy, a common mechanism of drug resistance involving drug-induced activation of pro-survival oncogenic processes, poses a challenge for the implementation of effective precision therapies. Here, we addressed...